Thymosin Alpha-1 vs AOD-9604: Which Peptide Is Right for You?

What Are These Two Peptides and Why Do Women Ask About Them?

These two compounds attract attention for very different reasons. Thymosin alpha-1 appears in oncology supportive care literature and chronic infection management, while AOD-9604 surfaces in weight-loss conversations. Women asking about both in the same breath are usually trying to decide whether to address immune fatigue, body composition, or both simultaneously.

The short answer is that they are not interchangeable. They act on different receptors, have different evidence bases, and suit different clinical pictures. Understanding which fits your situation requires separating marketing from published data.

Thymosin Alpha-1: The Immune Regulator

Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymic tissue and now produced synthetically. It is sold as thymalfasin (Zadaxin) in countries where it is licensed. Its primary action is on dendritic cells, natural killer cells, and T-helper cell maturation. In a 2010 review by Romani et al. Published in the Annals of the New York Academy of Sciences, thymosin alpha-1 demonstrated restored T-cell function in patients with chronic hepatitis B and C and was used adjunctively in cancer immunotherapy protocols. That paper described improvements in CD4+ counts and T-cell proliferative responses across multiple Phase II and Phase III trials.

For women specifically, thymic function declines with age and accelerates around menopause due to estrogen withdrawal. Estrogen receptors are expressed on thymic epithelial cells, which means the drop in estradiol during perimenopause directly affects thymic output. This is one reason some women in midlife notice more frequent infections and slower recovery.

AOD-9604: The Lipolytic Fragment

AOD-9604 is a synthetic analogue of amino acids 176 to 191 of human growth hormone. Heffernan et al., writing in Endocrinology in 2001, showed that this fragment stimulates lipolysis and inhibits lipogenesis in obese rodent models without activating the GH receptor, meaning it does not raise IGF-1 or cause insulin resistance at studied doses. That finding was the scientific rationale for developing it as a fat-targeted compound.

Human data is thin. A small Australian trial (METAOD001) tested oral AOD-9604 in overweight adults and found statistically non-significant weight loss compared to placebo after 12 weeks, leading the sponsor to halt further development of the oral form. Subcutaneous formulations used in current compounding practice have not been evaluated in published randomized controlled trials in women.

How Their Mechanisms Differ (And Why That Matters for Women)

The two peptides work on completely separate biological pathways. Thymosin alpha-1 binds Toll-like receptors on innate immune cells and promotes T-regulatory and Th1 cytokine activity. AOD-9604 acts on adipocyte receptors, specifically the beta-3 adrenoceptor pathway, to enhance fat oxidation. One is an immune signal; the other is a metabolic signal. Combining them is physiologically plausible but has not been studied.

Why the Menstrual Cycle Changes the Picture

Immune function fluctuates across the menstrual cycle. Natural killer cell activity peaks in the follicular phase and drops during the luteal phase due to rising progesterone, which has immunosuppressive properties that protect an implanting embryo. If you are using thymosin alpha-1 for immune support, the luteal-phase suppression may blunt its effect during that window. No trial has measured thymosin alpha-1 efficacy across cycle phases, so this is mechanistic reasoning, not direct evidence.

Metabolic rate also fluctuates. Resting energy expenditure rises by approximately 7 to 10 percent during the luteal phase compared to the follicular phase. If AOD-9604 enhances lipolysis, its magnitude of effect may differ across cycle phases. Again, no trial has tested this directly in women.

Perimenopause and Menopause

Visceral fat accumulates preferentially during perimenopause due to falling estradiol, rising cortisol, and shifting adipokine patterns. The Menopause Society notes that the metabolic shift toward central adiposity increases cardiovascular and insulin-resistance risk independent of total body weight. AOD-9604's proposed mechanism of preferential visceral lipolysis is biologically attractive in this context, but no trial has enrolled perimenopausal women specifically.

Thymosin alpha-1 may be more relevant in post-menopause, when cumulative thymic involution compounds estrogen-related immune decline. A 2010 analysis by Romani and colleagues found that older patients with impaired baseline T-cell counts showed the largest immunological responses to thymalfasin, which may be relevant for post-menopausal women who carry heavier infectious disease burdens.

PCOS

Women with PCOS carry both immune dysregulation and metabolic dysfunction, making both peptides theoretically relevant. Chronic low-grade inflammation is measurable in PCOS, with elevated CRP, IL-6, and TNF-alpha in multiple cohort studies. Thymosin alpha-1's anti-inflammatory and immune-regulatory properties could theoretically address that inflammatory background.

AOD-9604 is potentially relevant because insulin resistance drives androgen excess in PCOS, and reducing visceral fat may improve insulin sensitivity. The Heffernan animal data showed no worsening of glucose tolerance, which is a meaningful safety consideration in a population already at risk for type 2 diabetes. Neither peptide has been studied in PCOS populations. Any use is off-label and extrapolated.

Head-to-Head Efficacy: What the Evidence Actually Shows

No published randomized controlled trial has compared thymosin alpha-1 directly against AOD-9604. The two compounds have not been tested in overlapping populations or for overlapping outcomes. Comparing them head-to-head requires acknowledging that the exercise is a synthesis of separate evidence streams, not a reading of a single trial. This gap is worth naming plainly.

Thymosin Alpha-1 Evidence Summary

The strongest evidence for thymosin alpha-1 comes from viral hepatitis trials and cancer adjuvant studies. In hepatitis B, thymalfasin at 1.6 mg subcutaneously twice weekly for 6 months produced seroconversion rates of approximately 40 percent in some trials, compared to 10 to 15 percent with placebo. A meta-analysis of thymalfasin in hepatitis C showed improved sustained virologic response when added to interferon therapy.

These are specific populations with severe immune deficits. Extrapolating those results to a generally healthy woman seeking immune optimization is a significant leap, and clinicians should be transparent about that gap. The FDA has not approved thymalfasin for any indication in the United States. It is available as a compounded peptide through licensed 503A or 503B pharmacies.

AOD-9604 Evidence Summary

Heffernan et al. established the lipolytic mechanism in rodents in 2001. The Australian METAOD001 human trial attempted to translate that finding to an oral formulation in overweight adults but did not reach statistical significance for weight loss at 12 weeks. No published human trial using subcutaneous AOD-9604 for weight or fat loss in women has been completed as of January 2025.

The FDA classified AOD-9604 as a new molecular entity in 2014, which has complicated its compounding status. Clinicians prescribing it through compounding pharmacies do so under significant regulatory uncertainty, and women should be aware that supply quality and dosing consistency vary between compounders.

WomanRx Life-Stage Evidence Rating for These Two Peptides:

| Life Stage | Thymosin Alpha-1 Relevance | AOD-9604 Relevance | |---|---|---| | Reproductive years (PCOS) | Moderate (inflammation data extrapolated) | Moderate (insulin sensitivity, no trials) | | Trying to conceive | Contraindicated, discontinue first | Contraindicated, discontinue first | | Perimenopause | High (thymic decline + immune shift) | High (visceral fat, no trials in peri) | | Post-menopause | High (immune senescence) | Moderate (visceral fat, no trials) | | Autoimmune conditions | Caution, needs specialist oversight | Lower relevance |

This framework is a clinical synthesis, not derived from a single published source. It is intended to help you structure a conversation with your provider, not to replace that conversation.

Pregnancy, Lactation, and Contraception

Both thymosin alpha-1 and AOD-9604 are contraindicated during pregnancy. Neither has been studied in pregnant women, and the mechanism of action of each raises theoretical concerns. Thymosin alpha-1 modulates immune tolerance, a process critical to pregnancy maintenance. Any exogenous disruption of that balance carries theoretical risk of pregnancy loss or immune-mediated placental injury. ACOG advises against any unstudied immunomodulatory agent during pregnancy absent compelling clinical necessity.

AOD-9604 stimulates lipolysis in a physiological state where fat mobilization is tightly regulated to support fetal growth. Animal reproductive toxicology data for AOD-9604 are not published in peer-reviewed literature, which means the risk to a developing embryo or fetus is genuinely unknown. Unknown risk in pregnancy is treated as presumed risk under standard clinical practice.

Trying to Conceive

Discontinue both peptides at least one full menstrual cycle before attempting conception. If you are undergoing assisted reproduction with ASRM-protocol ovarian stimulation, discuss peptide use with your reproductive endocrinologist before your stimulation cycle begins.

Lactation

Neither peptide has measurable pharmacokinetic data in breast milk. Peptides are generally degraded in the gastrointestinal tract and have low oral bioavailability, which would limit infant exposure through nursing. However, absence of data is not the same as confirmed safety. The National Institutes of Health LactMed database does not contain entries for either thymosin alpha-1 or AOD-9604 as of January 2025, reflecting the absence of lactation-specific studies. Most women's health clinicians advise stopping both during breastfeeding until data exist.

Contraception Requirements

Neither peptide is a known teratogen in the way that isotretinoin or methotrexate are, so a formal Risk Evaluation and Mitigation Strategy (REMS) program is not required. However, because the risk to pregnancy is unstudied rather than proven safe, clinicians prescribing these peptides should document that the patient is using reliable contraception or is not at risk of pregnancy.

Who This May Be Right For (And Who Should Avoid It)

Thymosin Alpha-1 May Fit You If:

You have a diagnosed immune deficit, recurrent viral infections, or are in active cancer supportive care under oncology supervision. Post-menopausal women with documented immune senescence and frequent infections represent the population where extrapolation from the published evidence is most reasonable. Women with autoimmune conditions should approach thymosin alpha-1 with caution and specialist oversight because stimulating T-cell activity in the context of autoimmunity carries theoretical risk of flare.

AOD-9604 May Fit You If:

You are in perimenopause or post-menopause with documented central adiposity, are already optimizing diet and resistance training, and are looking for adjunctive metabolic support. Women with PCOS who have plateaued on metformin or GLP-1 therapy and who want to specifically target visceral fat could ask their provider whether AOD-9604 merits a trial, with the understanding that the human evidence base is very thin.

Neither Is Appropriate If:

You are pregnant, trying to conceive within the next cycle, or breastfeeding. Women with active autoimmune hepatitis should not use thymosin alpha-1 without hepatologist approval, given its mechanism. Women with a history of growth-related malignancies should discuss AOD-9604 with their oncologist before use, because any GH-pathway adjacent compound warrants caution in that context even if IGF-1 stimulation is not its primary action.

Dosing, Administration, and Monitoring for Women

Thymosin Alpha-1 Dosing

The dose used in published hepatitis trials was 1.6 mg subcutaneously twice weekly. Compounding prescriptions for immune support in otherwise healthy adults often use the same dose, though some protocols use 1.6 mg once weekly as a maintenance dose. Injection sites rotate among the abdomen, thigh, and upper arm. Local injection-site reactions are the most common adverse effect, occurring in approximately 10 to 15 percent of users in trial data.

Monitoring should include a baseline CBC with differential, CRP, and if autoimmunity is a concern, ANA and anti-dsDNA. Repeat CBC at 8 to 12 weeks. No thyroid-specific monitoring is required, but given that post-menopausal women carry higher rates of subclinical hypothyroidism, baseline TSH is reasonable before starting any new agent that could affect energy or immune markers.

AOD-9604 Dosing

Compounding protocols most often use 250 to 500 mcg subcutaneously once daily, typically in the morning before food to use the fasted lipolytic state. The Heffernan animal data used weight-adjusted dosing; translation to human dosing is not based on pharmacokinetic bridging studies but on clinical convention in compounding practice.

Monitoring should include fasting glucose, fasting insulin, and HOMA-IR at baseline and at 12 weeks, given the metabolic rationale for use. Women with PCOS should also track menstrual regularity, as changes in visceral adiposity can shift androgen levels and cycle pattern.

The Evidence Gap: What We Do Not Know About Women

Women were consistently under-represented in the foundational trials for both peptides. The Romani 2010 review drew primarily on hepatitis and cancer populations that skewed male in enrollment. The Heffernan 2001 study used male and female obese mice but did not report sex-stratified outcomes. Human AOD-9604 trials used mixed-sex adult populations without publishing sex-disaggregated results.

Sex differences in peptide pharmacokinetics are real. Body composition differences between men and women affect volume of distribution. Hormonal fluctuation across the cycle alters hepatic enzyme activity, which may change peptide half-life. The NIH policy requiring sex as a biological variable in preclinical research has only been in place since 2016, meaning older foundational studies for these peptides predate that requirement. Clinicians prescribing these compounds to women are, in part, extrapolating from male-dominant data. Women deserve to know that.

Can You Switch Between Them or Use Both?

There is no pharmacological interaction between thymosin alpha-1 and AOD-9604 that would make combination use inherently dangerous based on known mechanisms. The two pathways, immune modulation and adipocyte lipolysis, do not directly intersect. Some compounding protocols offer both simultaneously for women who have both immune and metabolic goals.

Switching from one to the other is straightforward. There is no washout requirement based on published data, because neither compound accumulates with long half-life in the way that depot medications do. Thymosin alpha-1 has an estimated half-life of approximately 2 hours after subcutaneous injection. AOD-9604 has a similarly short half-life based on the GH fragment pharmacokinetics reported in early growth hormone research. Both clear within 24 hours under normal circumstances.

If you are switching because one did not produce the expected benefit, discuss with your provider whether the lack of response was related to dose, duration, baseline immune or metabolic status, or whether the original goal was realistic given the evidence base.

Cost, Access, and What to Ask Your Provider

Compounded thymosin alpha-1 typically costs between $150 and $350 per month depending on dose and compounding pharmacy. Compounded AOD-9604 runs approximately $80 to $200 per month. Neither is covered by insurance because neither holds an FDA-approved indication for the conditions for which they are being prescribed. The FDA's guidance on compounded drugs clarifies that compounded peptides may be prescribed when a licensed prescriber determines a clinical need exists that is not met by an approved drug.

Before starting either, ask your provider these specific questions. What is my baseline immune or metabolic marker that this peptide is expected to move? How will we measure response at 8 to 12 weeks? What is the stopping criterion if I do not respond? Do you have experience prescribing this in women at my life stage?

A provider who cannot answer those questions with specific numbers and a monitoring plan is not providing evidence-based compounding care.